The US Food and Drug Administration has approved a new drug, WinRevair, for the treatment of pulmonary arterial hypertension (PAH). PAH is a rare and serious condition that affects the heart and lungs. WinRevair has shown promising results in clinical trials and is expected to provide a new treatment option for patients with PAH.

Read more at: https://www.reuters.com/technology/us-charges-kucoin-crypto-exchange-with-anti-money-laundering-failures-2024-03-26/

Gabriel Whitaker, journalist
Gabriel Whitaker

$20 / month
ShortyPRO Monthly
Monthly ShortyPRO subscription:
  • No ads!
  • Full access to all categories:
    • Business
    • Tech
    • Health
    • Sport
    • Entertainment
    • World
+ All future updates and features!
Free trial
ShortyPRO Trial
ShortyPRO experience for two weeks:
  • No ads!
  • Full access to all categories:
    • Business
    • Tech
    • Health
    • Sport
    • Entertainment
    • World
shortyok

FREE
VIEW